Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea

Exclusion Criteria

• •Pregnant or breastfeeding woman
• •Subject showing cutaneous marks on the experimental areas, which could interfere with the assessment of skin reactions (pigmentation troubles, scar elements, over-developed pilosity, ephelides and naevi in too great quantity, sunburn)
• •Subject with documented allergy or reactivity to products of the same category than the tested one
• •Subject with documented allergies to study product components
• •Subject with history of malignant melanomas (Dubreuilh melanosis…)
• •Subject with unbalanced hormonal treatment
• •Subject with forecast of initiation of a hormonal treatment or change of the usual hormonal treatment during the study period
• •Subject with forecast of sun or UVA exposure (UV lamps) during the study period
• •Subject not willing to use sun protective clothes orhat if exposed to the sun
• •Subject not willing to respect the methods of use of the treatment, study product and sunscreen
• •Subject with anti-ageing or aesthetic treatment during the last 6 months: botox or botox like products, peelings, plastic surgery, hyaluronic acid treatment, Plasma Rich Platelets treatment, or any other specific treatments prone to change the skin aspect
• •Subject with antibiotic, anti-allergic, anti-inflammatory treatment or treatment with patent medicines containing Vitamin A acid or its derivatives within 4 weeks and during the study (if therapeutic requirement: exclusion foreseen),
• •Subject with systemic disorder: cardiovascular, pulmonary, digestive, neurologic, psychiatric, genital, urinary, haematological, endocrine
• •Subject presenting chronic diseases with impact on skin
• •Subject who has undergone a bilateral mastectomy with lymph node removal, a unilateral mastectomy with lymph node removal within the last year, or a bilateral axillary lymph node removal,
• •Subject with a history of immune deficiency or auto-immune disease, treated for malignancy within 6 months prior to enrolment or who are currently under treatment for asthma or diabetes, forecast of vaccination during the test period or last vaccination within 3 weeks before the study.
• •Subject receiving local treatment for rosacea (cyclins, isotretinoin) or who has undergone local active treatment for rosacea (erythromycin, metronidazole, benzoyl peroxide, ivermectin) within 4 weeks before inclusion in the study
• •Subject who has had oral treatment with metronidazole or cyclins within 4 weeks before inclusion in the study
• •Subject who has had topical or oral anti-inflammatory and/or antiallergy treatment (corticosteroid, antihistamine, anti-inflammatory drugs, immunosuppressives) within 4 weeks before inclusion in the study
• •Subject who has had oral treatment with retinoids within 2 months before inclusion in the study
• •Subject currently receiving electrocoagulation or laser treatment for telangiectasia